Minglei Zhuo
YOU?
Author Swipe
View article: Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 Open
PURPOSE For patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor ( EGFR ) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment options is limited. PATIENTS AND METHODS …
View article: Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)
Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058) Open
Objective To investigate the efficacy of anlotinib, an antiangiogenic multikinase inhibitor, as an add-on therapy to first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) for patients with EGFR -mutant non-smal…
View article: The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial
The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial Open
RENAISSANCE study, NCT04606303, initiated on October 27, 2020.
View article: Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications
Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications Open
YAP1 expression was independent of molecular subtypes. YAP1-positive tumors may exhibit enhanced responsiveness to immunotherapy/NEUROD1-targeted therapy, while YAP1-negative tumors could benefit from ASCL1/DLL3-targeted approaches. Prospe…
View article: Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced <scp>NSCLC</scp> Patients With Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations: A Multicenter, Phase <scp>II</scp> Trial
Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced <span>NSCLC</span> Patients With Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations: A Multicenter, Phase <span>II</span> Trial Open
Background Studies indicated that afatinib combined with angiogenesis inhibitor may achieve promising efficacy in non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor ( EGFR ) mutations. Methods This is a multi…
View article: Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study
Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study Open
MP component and risk factors might be considered critical features for patients with stage I lung adenocarcinomas and may inform the selection of patients who may benefit from adjuvant chemotherapy although no randomized evidence is avail…
View article: Comparative efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy versus combined EGFR-TKI and chemotherapy in resectable EGFR-mutant non-small cell lung cancer: a real-world multicenter retrospective study
Comparative efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy versus combined EGFR-TKI and chemotherapy in resectable EGFR-mutant non-small cell lung cancer: a real-world multicenter retrospective study Open
Neoadjuvant EGFR-TKI therapy combined with chemotherapy demonstrated promising pathological responses and perioperative safety, supporting its feasibility in resectable EGFR-mutant NSCLC.
View article: Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i> -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i> -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial Open
Objective To compare the efficacy and safety of sacituzumab tirumotecan (sac-TMT) with docetaxel in patients with locally advanced or metastatic epidermal growth factor receptor ( EGFR) -mutated non-small cell lung cancer (NSCLC) after pre…
View article: Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study
Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study Open
National Natural Science Foundation of China (82072583); Beijing Municipal Administration of Hospitals Incubating Program (PX2020044); Beijing Hospitals Authority Youth Programme (QML20231113); Science Foundation of Peking University Cance…
View article: Chinese Expert Consensus on the Diagnosis and Treatment of Inflammatory Myofibroblastic Tumor
Chinese Expert Consensus on the Diagnosis and Treatment of Inflammatory Myofibroblastic Tumor Open
Inflammatory myofibroblastic tumor (IMT) is a rare spindle‐cell neoplasm. IMT currently suffers from a paucity of standardized diagnostic and therapeutic guidelines. The Chinese expert consensus committee on the diagnosis and treatment of …
View article: Characteristics and dynamics of microbial communities in Dermatophagoides farinae: Insights Across Developmental Stages
Characteristics and dynamics of microbial communities in Dermatophagoides farinae: Insights Across Developmental Stages Open
Background Dermatophagoides farinae causes human allergic diseases and contains a large number of microbes. The structure of the microbial community is an essential prerequisite for understanding the intricate symbiotic relationships betw…
View article: Whole-section digital analysis of immune profiles in surgically resected small cell lung carcinoma and their associations with molecular subtypes
Whole-section digital analysis of immune profiles in surgically resected small cell lung carcinoma and their associations with molecular subtypes Open
This study highlights the heterogeneity of the TIME across molecular subtypes of SCLC. The SCLC-P subtype and MHC I expression may serve as predictive biomarkers for immunotherapy response, while peri-TLS density and stromal PD-L1 expressi…
View article: Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)
Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432) Open
Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for patients with non-small cell lung cancer (NSCLC). In spite of durable responses in some patients, many patients develop early disease progression during the ICI t…
View article: Efficacy of neoadjuvant toripalimab plus chemotherapy and the role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer (RENAISSANCE study): a prospective phase II trial
Efficacy of neoadjuvant toripalimab plus chemotherapy and the role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer (RENAISSANCE study): a prospective phase II trial Open
Introduction: Neoadjuvant chemoimmunotherapy does not benefit all non-small cell lung cancer (NSCLC) patients, and reliable biomarkers are urgently needed. We conducted this prospective phase II trial of neoadjuvant chemoimmunotherapy to e…
View article: Women patients with small‐cell lung cancer using immunotherapy in a real‐world cohort achieved long‐term survival
Women patients with small‐cell lung cancer using immunotherapy in a real‐world cohort achieved long‐term survival Open
Background Usage of immune checkpoint inhibitors (ICIs) has prolonged the overall survival (OS) of patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). In clinical trials, males accounted for a large proportion, leading to the u…
View article: Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study
Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study Open
Background The incidence of neuroendocrine neoplasms (NENs) is rising rapidly worldwide. However, there are few reports on these heterogeneous diseases in China. Our study aimed to explore the epidemiological characteristics of NENs in Bei…
View article: Genetic and phenotypic profiling of single living circulating tumor cells from patients with microfluidics
Genetic and phenotypic profiling of single living circulating tumor cells from patients with microfluidics Open
Accurate prediction of the efficacy of immunotherapy for cancer patients through the characterization of both genetic and phenotypic heterogeneity in individual patient cells holds great promise in informing targeted treatments, and ultima…
View article: 172P Real-world data of anolotinib for lung cancers with liver metastases in China
172P Real-world data of anolotinib for lung cancers with liver metastases in China Open
Despite the high incidence rate and poor prognosis of lung cancers with liver metastases, effective treatment for this population remains an unmet need. Anlotinib (a novel anti-angiogenesis agent) could reprogramme the tumor microenvironme…
View article: Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas Open
This work demonstrated striking gene distinctions in GEPNEC compared with LNEC and adenocarcinoma and their clinical utility.
View article: P2.05-19 Prediction of Durable Response to Immunotherapy by Early Dynamic in ctDNA and Peripheral Immune Features in NSCLC
P2.05-19 Prediction of Durable Response to Immunotherapy by Early Dynamic in ctDNA and Peripheral Immune Features in NSCLC Open
View article: Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study
Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study Open
Background The incidence of neuroendocrine neoplasms (NENs) is rising rapidly worldwide. However, there are few reports on these heterogeneous diseases in China. Our study aimed to explore the epidemiological characteristics of NENs in Bei…
View article: Characterization of Lung and Oral Microbiomes in Lung Cancer Patients Using Culturomics and 16S rRNA Gene Sequencing
Characterization of Lung and Oral Microbiomes in Lung Cancer Patients Using Culturomics and 16S rRNA Gene Sequencing Open
The relationship between lung microbiota and cancer has been explored based on DNA sequencing; however, culture-dependent approaches are indispensable for further studies on the lung microbiota. In this study, we applied a comprehensive ap…
View article: Data from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells
Data from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells Open
Purpose:Genomic analyses of small-cell lung cancer (SCLC) are limited by the availability of tumor specimens. This study aimed to investigate the suitability of single-cell sequencing of circulating tumor cells (CTC) as a method of inferri…
View article: Table S2-S11 from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells
Table S2-S11 from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells Open
Supplementary Tables 2-11
View article: Figure S1-S6 from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells
Figure S1-S6 from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells Open
Supplementary Figures 1-6
View article: Supplemental Data from Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases
Supplemental Data from Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases Open
Supplementary Figure S1-S16: Figure S1: landscape of variants in all samples; Figure S2: cancer cell fraction of each mutation; Figure S3: patient screen; Figure S4: high frequency CNV in each sample; Figure S5: SNV disparity between PT an…
View article: Supplementary Data from Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases
Supplementary Data from Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases Open
Supplementary Table S2's detail information of germline mutations in each patient
View article: Figure S1-S6 from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells
Figure S1-S6 from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells Open
Supplementary Figures 1-6
View article: Table S2-S11 from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells
Table S2-S11 from Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells Open
Supplementary Tables 2-11
View article: Supplementary Data from Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases
Supplementary Data from Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases Open
Supplementary Table S2's patient detail information